Clinical Trial Update: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study of ORIC-533 in relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• ORIC-533

Snippet

Sponsor: ORIC Pharmaceuticals | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED